AstraGin®, Developed by NuLiv Science, Demonstrates Improvements in Gut Health in Human Clinical Trial

BREA, Calif., April 3, 2023 /PRNewswire/ — A groundbreaking human clinical trial published in the Journal of Biochemistry and Biotechnology reveals AstraGin®’s significant impact on various factors related to gut health in patients with Ulcerative Colitis (UC).

AstraGin® human study positions the ingredient as a solution for gut health and beneficial probiotic growth

In this study, UC patients took one capsule of AstraGin® before breakfast and dinner for three months, following a 100mg per day protocol. The results demonstrated that AstraGin® effectively improved intestinal barrier integrity, increased the population of beneficial bacteria, and mitigated the growth of harmful bacteria in the gut.

The study reported notable increases in populations of good bacteria, including a 420% increase in Faecalibacterium prausmitzii and a 180% increase in Bifidobacterium adolescentis, among others. These probiotics play a crucial role in maintaining a healthy gut environment.

Moreover, AstraGin® was shown to significantly decrease the growth of harmful bacteria, with a 98% decrease in Prevotella and a mitigating Enterobacteriaceae with a mere 14% increase compared to a 614% increase observed in the placebo group.

In addition, participants in the AstraGin® group experienced an 11% increase in neutrophil cells and a 20.5% increase in lymphocyte immune cells, enhancing the body’s immune response. AstraGin® also improved L-arginine absorption, with the area under the curve (AUC) of L-arginine in the AstraGin® group being 49.7% higher than the placebo group. Furthermore, the trial showed a positive impact on ghrelin, an appetite hormone often affected by gut health challenges.

These significant findings by NuLiv Science demonstrate the potential of AstraGin® to support overall gut health and well-being, positioning it as a promising solution for individuals with UC and other gut-related challenges.

Richard Wang, CEO at NuLiv Science noted, “The professors behind AstraGin® explored multiple pathways on how AstraGin® supports bioavailability. We’ve been down a rabbit hole of sorts the past seven years looking at different gut related mechanisms. I know we’re still in the early stages but the data is promising in that AstraGin® supports a better intestinal environment.”

For more information about AstraGin® and the clinical trial, please visit or contact the company’s marketing director, Josh Beaty, at [email protected].


NuLiv Science, a Certified B-Corp, specializes in the research and development of evidence-based ingredients via traditional and Western scientific methods. Since 1997, the company has served our clients’ sourcing and research needs with an emphasis on quality and efficacy.

Our clientele base, from large MLMs and global nutrition brands to natural health practitioners, is as diverse as our ingredient portfolio. NuLiv Science’s experienced research team and network of scientific advisors can help with formulations, efficacy, standardization analytics, and the production of high-potency extracts.

Cision View original content to download multimedia:

SOURCE Nuliv Science

AstraGin®, Developed by NuLiv Science, Demonstrates Improvements in Gut Health in Human Clinical Trial WeeklyReviewer

PR Newswire Sports News

World Reviewer Staff
World Reviewer Staff
The first logical thought has to be "no way". I'm the World Observer! Ill find and share important news all day.

Latest articles

Earnings Disclosure

WeeklyReviewer earns primarily through affiliates and ads. We don’t encourage anyone to click on ads for any other purpose but your own. We recommend products and services often for our readers, and through many we will earn commissions through affiliate programs.

Related articles